References
- Ma J, Jemal A. Breast cancer statistics. In: Breast Cancer Metastasis and Drug Resistance. Springer; NY, USA; 2013. p. 1-18
- Wright SE. Immunotherapy of breast cancer. Expert Opin Biol Ther 2012;12(4):479-90
- Vrbic S, Pejcic I, Filipovic S, et al. Current and future anti-HER2 therapy in breast cancer. J buon 2013;18(1):4-16
- Holmes JP, Gates JD, Benavides LC, et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008;113(7):1666-75
- Fang L, Barekati Z, Zhang B, et al. Targeted therapy in breast cancer: what’s new. Swiss Med Wkly 2011;141:w13231
- Jelovac D, Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol 2012;13(2):230-9
- Milani A, Sangiolo D, Montemurro F, et al. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013;24(7):1740-8
- Mittendorf EA, Clifton GT, Holmes JP, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012;118(10):2594-602
- Wiedermann U, Wiltschke C, Jasinska J, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2010;119(3):673-83
- Hamilton E, Blackwell K, Hobeika AC, et al. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med 2012;10:28
- Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011;9(1):16-32
- Tagliabue E, Campiglio M, Pupa SM, et al. The HER2 world: better treatment selection for better outcome. J Natl Cancer Inst Monogr 2011;2011(43):82-5
- Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 2012;12(12):1597-611
- Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12(4):237-51
- Naujokat C. Targeting Human Cancer Stem Cells with Monoclonal Antibodies. J Clin Cell Immunol 2012; (S5:007)
- Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010;28(25):4006-12
- Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012;131(2):371-83
- Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85
- Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375(9712):377-84
- Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 2011;6(6):e21030
- Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12(3):236-44
- Yerushalmi R, Gelmon K. Treatment beyond progression: is it moving from belief to evidence? Oncologist 2010;15(8):796-8
- Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365(14):1273-83
- Huang Y, Fu P, Fan W. Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2-Overexpressing Metastatic Breast Cancer. Curr Drug Targets 2013;14(8):889-98
- Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28(8):1301-7
- A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination. With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00398567&Search=Search
- Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00741260&Search=Search
- A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00445458&Search=Search
- Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00915018&Search=Search
- Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00706030&Search=Search
- Tsang R, Finn R. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012;106(1):6-13
- LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01125566&Search=Search
- Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00372424&Search=Search
- Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00243503&Search=Search
- Andre F, Campone M, O’Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;28(34):5110-15
- Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011;125(2):447-55
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00620594&Search=Search
- Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01132664&Search=Search
- Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2–overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25(34):5410-17
- Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17(15):5132-9
- CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00412412&Search=Search
- Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00526045&Search=Search
- Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91
- Boyraz B, Sendur MA, Aksoy S, et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 2013;29(4):405-14
- Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-405
- Krop I, LoRusso P, Miller K, et al. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. In: Annals of oncology. Oxford Univ Press, Oxford, England, 2010; p. 97-97
- Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30(26):3234-41
- Dieras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Cough 2010;23:34-3
- Capelan M, Pugliano L, De Azambuja E, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 2013;24(2):273-82
- Cortés J, Baselga J, Petrella T, et al. Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2-positive breast cancer. J Clin Oncol 2009;27(15S):1022
- Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71
- Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(1):25-32
- Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res 2011;71(Suppl 24):112s
- Von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant Pertuzumab and HerceptIN initial therapy of breast cancer: APHINITY (BIG 4–11/BO25126/TOC439g). Cancer Res 2011;71(Suppl 24):602s
- A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01026142&Search=Search
- A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01120184&Search=Search
- Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00522457&Search=Search
- CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00635245&Search=Search
- A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00882674&Search=Search
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00699491&Search=Search
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00728949&Search=Search
- A Study of Dalotuzumab (MK0646) in Breast Cancer Patients. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00759785&Search=Search
- The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01220570&Search=Search
- A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM3). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01605396&Search=Search
- Di Cosimo S, Bendell J, Cervantes-Ruiperez A, et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;3008
- Yardley DA. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety. Clin Breast Cancer 2010;10(2):119-29
- Hurvitz S, Pegram M, Lin L, et al. Final results of a phase ii trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. In: Cancer Research. Amer Assoc Cancer Research; 615 Chestnut St, 17th Floor, Philadelphia, PA 19106-4404 USA: 2009; 854S-854S
- Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27(30):4966-72
- Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47
- Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60
- A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1). Available from: www.clinicaltrials.gov/ct2/results?term=NCT00262067&Search=Search
- A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2). Available from: www.clinicaltrials.gov/ct2/results?term=NCT00281697&Search=Search
- Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012;118(12):3014-25
- Valachis A, Polyzos N, Patsopoulos N, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010;122(1):1-7
- Dickler M, Franco S, Stopeck A, et al. Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC). In: Cancer Research. American Association Cancer Research; PA, USA: 2009. p. 242S-S
- Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19(18):4917-24
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
- Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01502592&Search=Search
- Study of MDX-010 in Stage IV Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00083278&Search=Search
- Ribas A. Clinical development of the anti–CTLA-4 antibody tremelimumab. In: Seminars in oncology. Elsevier; The Netherland: 2010. p. 450-4
- Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010;16(13):3485-94
- Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J Immunol 2003;171(3):1272-7
- Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
- Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
- A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01928394&Search=Search
- CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01386502&Search=Search
- Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207(10):2187-94
- Li B, VanRoey M, Wang C, et al. Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors. Clin Cancer Res 2009;15(5):1623-34
- Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci 2008;105(8):3005-10
- Yen W, Fischer M, Lewicki J, et al. Targeting cancer stem cells and vasculature by a novel anti-delta-like 4 ligand (dll4) antibody for treatment of triple negative breast cancer. In: Cancer research. AACR; 2009. p. 788S-9S
- Witthauer J, Schlereth B, Brischwein K, et al. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110. Breast Cancer Res Treat 2009;117(3):471-81
- Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00635596&Search=Search
- Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci 2012;109(29):11717-22
- A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01973309&Search=Search
- Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res Treat 2013;138(1):1-12
- Arens R, van Hall T, van der Burg SH, et al. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. In: Seminars in immunology. Elsevier; The Netherland: 2013
- Ladjemi MZ, Jacot W, Chardes T, et al. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010;59(9):1295-312
- Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14(3):797-803
- Patil R, Clifton GT, Holmes JP, et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg 2010;210(2):140-7
- Holmes JP, Clifton GT, Patil R, et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2011;117(3):463-71
- Vreeland TJ, Clifton GT, Hale DF, et al. Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine. Cancer Res 2012;72:Suppl 24): Abstract nr P5-16-02
- Amin A, Benavides LC, Holmes JP, et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother 2008;57(12):1817-25
- Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010;116(2):292-301
- Sears AK, Perez SA, Clifton GT, et al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther 2011;11(11):1543-50
- Trappey F, Berry JS, Vreeland TJ, et al. A randomized phase II clinical trial of GP2 vaccine prevent recurrence in high-risk breast cancer patients: A planned interim analysis. J Clin Oncol 2013;31( suppl); abstr 3005
- Sotiriadou NN, Kallinteris NL, Gritzapis AD, et al. Ii-Key/HER-2/neu (776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 2007;56(5):601-13
- Holmes JP, Benavides LC, Gates JD, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;26(20):3426-33
- Benavides LC, Sears AK, Gates JD, et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines 2011;10(2):201-10
- Hale D, Perez S, Sears A, et al. An update of a Phase II trial of the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. In: san Antonio Breast Cancer Symposium (SABCS); San Antonio, TX, USA. 2011; p.6-10
- Kaumaya PT, Foy KC, Garrett J, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009;27(31):5270-7
- Dakappagari NK, Douglas DB, Triozzi PL, et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000;60(14):3782-9
- Mahdavi M, Keyhanfar M, Moreau V, et al. In silico Design of Discontinuous Peptides Representative of B and T-cell Epitopes from HER2-ECD as Potential Novel Cancer Peptide Vaccines. Asian Pac J Cancer Prev 2013;14(10):5973-81
- Schneble EJ, Berry JS, Trappey AF, et al. Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients. J Immunother Cancer 2013;1(Suppl 1):P236
- Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009;27(28):4685-92
- Patil R, Clifton GT, Litton JK, et al. Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting. J Clin Oncol 2013;31(Suppl); abstr 3096
- Curigliano G, Spitaleri G, Pietri E, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006;17(5):750-62
- Sangha R, Butts C. L-BLP25: a Peptide Vaccine Strategy in Non–Small Cell Lung Cancer. Clin Cancer Res 2007;13(15):4652s-4s
- Musselli C, Ragupathi G, Gilewski T, et al. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002;97(5):660-7
- Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6(5):1693-701
- MUC1 Vaccine for Triple-negative Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00986609&Search=Search
- Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 2011;10(3):1-20
- A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00925548&Search=Search
- Liu J-P, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta 2010;1805(1):35-42
- Carey LA, Hedican CA, Henderson GS, et al. Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers. Clin Cancer Res 1998;4(2):435-40
- Hashimoto Y, Murakami Y, Uemura K, et al. Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointest Surg 2008;12(1):17-28. discussion 28; 9
- Domchek SM, Recio A, Mick R, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007;67(21):10546-55
- Multipeptide Vaccine for Advanced Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00573495&Search=Search
- Buseman C, Wright W, Shay J. Is telomerase a viable target in cancer? Mutat Res 2012;730(1):90-7
- Multi-peptide Vaccine With Basilixumab for Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01660529&Search=Search
- Clinicaltrials. Available from: http://clinicaltrials.gov
- Mohit E, Rafati S. Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity. Mol Immunol 2013;56(4):599-611
- Berinstein NL, Karkada M, Morse MA, et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012;10:156
- Albrecht H. Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity. Immunotherapy 2012;4(7):671-4
- Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011;10(4):471-86
- Kageyama S, Kitano S, Hirayama M, et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 2008;99(3):601-7
- Kitano S, Kageyama S, Nagata Y, et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 2006;12(24):7397-405
- Moser C, Amacker M. Influenza Virosomes as Antigen Delivery System. In: Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Springer; NY, USA: 2013; p. 287-307
- Homhuan A. Virosome vaccines and their application in cancer immunotherapy. Asian Biomed 2010;3(4):365-73
- Sharma R, Yasir M. Virosomes: a Novel Carrier for Drug Delivery. Int J Pharm Tech Res 2010;2(4):2327-39
- Pevion Biotech Ltd. Available from: www.pevion.com
- Foy KC, Miller MJ, Moldovan N, et al. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012;1(7):1048-60
- Disis ML, Gad E, Herendeen DR, et al. A multiantigen vaccine targeting neu, igfbp-2, and igf-ir prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) 2013;6(12):1273-82
- Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine 2012;8(5):692-701
- Gritzapis AD, Voutsas IF, Lekka E, et al. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 2010;70(7):2686-96
- Wright SE. Immunotherapy of breast cancer. Expert Opin Biol Ther 2012;12(4):479-90
- Gray A, Raff AB, Chiriva-Internati M, et al. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 2008;222(1):316-27
- Morales JK, Kmieciak M, Knutson KL, et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010;123(1):39-49
- Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF). Available from: www.clinicaltrials.gov/ct2/results?term=NCT00095706&Search=Search
- Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00331552&Search=Search
- Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01479179&Search=Search
- MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01097460&Search=Search
- Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00006123&Search=Search
- Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00014430&Search=Search
- Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01512199&Search=Search
- Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00807859&Search=Search
- Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00028535&Search=Search
- Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01602406&Search=Search
- Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00039455&Search=Search
- Britten CD, Finn RS, Bosserman LD, et al. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer 2009;9(1):16-22
- Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00068757&Search=Search
- Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01434303&Search=Search
- BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00397501&Search=Search
- Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00006825&Search=Search
- Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast, Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01705340&Search=Search
- Storniolo A, Burris H, Overmoyer B, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. In: Breast cancer research and treatment. Springer; NY, USA: 2005; p. S64-S64
- Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00367250&Search=Search
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00004074&Search=Search
- Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00086957&Search=Search
- Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00258349&Search=Search
- Cameron D, Marreaud S, Zaman K, et al. LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial. J Clin Oncol 2010;28
- Combination Of Lapatinib With Carboplatin, Paclitaxel and Trastuzumab In Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00367471&Search=Search
- Safety Study of MGAH22 in HER2-positive Carcinomas. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01148849&Search=Search
- A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01745965&Search=Search
- BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02038010&Search=Search
- Trastuzumab & Pertuzumab Followed by T-DM1 in MBC. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01835236&Search=Search
- Tykerb Evaluation After Chemotherapy (TEACH): lapatinib Versus Placebo In Women With Early-Stage Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00374322&Search=Search
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00490139&Search=Search
- Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer. Available from www.clinicaltrials.gov/ct2/results?term=NCT00429299&Search=Search
- A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00567554&Search=Search
- Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00553358&Search=Search
- Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01437566&Search=Search
- A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01740336&Search=Search
- Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00928330&Search=Search
- A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients With Locally Recurrent Or Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00960960&Search=Search
- Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00803556&Search=Search
- Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00774878&Search=Search
- Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01632332&Search=Search
- Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00005023&Search=Search
- HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00003002&Search=Search
- Vaccine Therapy in Treating Patients With Metastatic Solid Tumors. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01376505&Search=Search
- Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01355393&Search=Search
- Vaccine Therapy in Treating Patients With Stage IV Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00791037&Search=Search
- Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01922921&Search=Search
- Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01570036&Search=Search
- Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00343109&Search=Search
- Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01729884&Search=Search
- Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00892567&Search=Search
- Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01532960&Search=Search
- Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00640861&Search=Search
- Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00079157&Search=Search
- Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00140738&Search=Search
- A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00058526&Search=Search
- Kapoor D, Vyas R, Lad C, Patel M. A multipurpose and novel carrier for drug delivery and targeting-virosomes. J Drug Deliv Ther 2013;3(5):143-7
- Sen K, Mandal M. Second generation liposomal cancer therapeutics: transition from laboratory to clinic. Int J Pharm 2013;448(1):28-43